Christopher Zou

Chris Zou

Hey, I'm Chris. I work at UCSF on functional genomics. I'm broadly interested in the physical and digital infrastructure required to speed up biology.

Not that long ago, I was a software engineer at Datavant and founded Health Engine. At Berkeley, I studied Computer Science and Biochemistry, and was involved in the Accel Scholars program.

If you would like to collaborate or if there's any way I can help you, please reach out at cwzou [at] berkeley [dot] edu.

Updates

[06/03/2025] Excited to work at FutureHouse for the summer.
[05/20/2025] I'm starting my PhD in Genetics at Stanford in the fall!
[02/25/2025] Our paper on epigenetic therapy in GBM is out in Neuro-Oncology.
[10/07/2024] In vivo perturb-seq published in Genome Biology.

Research

Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy

Katie Lin, Christopher Zou, Akane Hubbard, Sasha Sengelmann, Laine Goudy, I-Ching Wang, Rohit Sharma, Joanna Pak, Kyla Foster, Tomoko Ozawa, John F de Groot, Joanna Phillips, Harish N Vasudevan, David R Raleigh, Alexander Marson, Niren Murthy, Luke A Gilbert, Mitchel S Berger, S John Liu
Neuro-Oncology, 2025

We show that transient delivery of a site-specific epigenetic memory editor can induce stable, complete, and multiplexed suppression of target genes for therapeutic application in GBM.

In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma

S. John Liu, Christopher Zou, Joanna Pak, Alexandra Morse, Dillon Pang, Timothy Casey-Clyde, Ashir A. Borah, David Wu, Kyounghee Seo, Thomas O'Loughlin, Daniel A. Lim, Tomoko Ozawa, Mitchel S. Berger, Roarke A. Kamber, William A. Weiss, David R. Raleigh, Luke A. Gilbert
Genome Biology, 2024

We developed the first in vivo perturb-seq platform in intact tumors, providing a target discovery and data generation tool.

Chris Zou

Updates

Research

Fun stuff

Bookshelf